Literature DB >> 25927503

Quantitative analysis of receptor allosterism and its implication for drug discovery.

Rumin Zhang1, Michael Kavana.   

Abstract

INTRODUCTION: G protein-coupled receptors represent the largest class of druggable targets and are known to be modulated by both orthosteric agonists and positive/negative allosteric modulators (PAMs/NAMs). Proper experimental design and data analysis for the dose matrix between an agonist and PAM or NAM are critical to elucidate the key parameters for understanding molecular mechanism and structure-activity relationship (SAR) in drug discovery. AREAS COVERED: The authors provide an overview and best practice recommendations on the quantitative analysis of receptor allosterism. The authors propose a simple classification system for receptor modulators on the basis of their efficacy and affinity modifiers. The authors also outline the optimal assay designs for both fixed dose screening and dose matrix study of receptor modulators. EXPERT OPINION: The authors recommend the global curve fitting approach to reliably yield system- and modulator-specific parameters for SAR ranking. Furthermore, the authors suggest that the uncertainty in maximal system response has insignificant impact on SAR ranking. The authors anticipate that systems pharmacology models integrating both binding kinetics and functional allosterism will be needed to address the inherent limitations of current allosterism models.

Entities:  

Keywords:  G protein-couple receptor; Monte Carlo simulation; agonism; allosteric two-state model; bitopic or dualsteric agonist; full agonist; global curve fitting; negative allosteric modulators; operational model; orthosterism; partial agonist; positive allosteric modulator; receptor allosterism; silent allosteric modulator; β supremacy

Mesh:

Substances:

Year:  2015        PMID: 25927503     DOI: 10.1517/17460441.2015.1041498

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  4 in total

1.  MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate.

Authors:  Douglas C Beshore; Christina N Di Marco; Ronald K Chang; Thomas J Greshock; Lei Ma; Marion Wittmann; Matthew A Seager; Kenneth A Koeplinger; Charles D Thompson; Joy Fuerst; George D Hartman; Mark T Bilodeau; William J Ray; Scott D Kuduk
Journal:  ACS Med Chem Lett       Date:  2018-04-30       Impact factor: 4.345

2.  Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators.

Authors:  Daniel E O'Brien; Douglas M Shaw; Hyekyung P Cho; Alan J Cross; Steven S Wesolowski; Andrew S Felts; Jonas Bergare; Charles S Elmore; Craig W Lindsley; Colleen M Niswender; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2018-03-15       Impact factor: 4.436

3.  Estimation of the receptor-state affinity constants of ligands in functional studies using wild type and constitutively active mutant receptors: Implications for estimation of agonist bias.

Authors:  Frederick J Ehlert; Richard S L Stein
Journal:  J Pharmacol Toxicol Methods       Date:  2016-10-07       Impact factor: 1.950

4.  Quantitative Measure of Receptor Agonist and Modulator Equi-Response and Equi-Occupancy Selectivity.

Authors:  Rumin Zhang; Michael Kavana
Journal:  Sci Rep       Date:  2016-04-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.